Monoclonal antibody capture and viral clearance by cation exchange chromatography

Biotechnology and Bioengineering

Volumn 109, Issue 8, 2012, Pages 2048-2058

  Miesegaes, G R ^a   Lute, S ^a   Strauss, D M ^b   Read, E K ^a   Venkiteshwaran, A ^b   Kreuzman, A ^b   Shah, R ^a   Shamlou, P ^b   Chen, D ^b   Brorson, K ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Cation exchange chromatography; Monoclonal antibodies; Viral clearance

Indexed keywords

CATION EXCHANGE CHROMATOGRAPHY; ISO-ELECTRIC POINTS; OPERATION OPTIMIZATION; POST-PRODUCTION; PRODUCT PURITY; PROTEIN A CHROMATOGRAPHY; THERAPEUTIC MONOCLONAL ANTIBODIES; THREE MODELS; VIRAL CLEARANCE;

MONOCLONAL ANTIBODIES; OPTIMIZATION; POSITIVE IONS; SURFACE PLASMON RESONANCE; VIRUSES;

CHROMATOGRAPHY;

MONOCLONAL ANTIBODY; RESIN;

ANALYTICAL EQUIPMENT; ANTIBODY CAPTURE; ARTICLE; BACTERIOPHAGE; CONTROLLED STUDY; IMMUNOASSAY; ION EXCHANGE CHROMATOGRAPHY; ISOELECTRIC POINT; MOLECULAR MODEL; PORCINE PARVOVIRUS; PROCESS DESIGN; PROCESS OPTIMIZATION; VIRAL CLEARANCE; VIRUS PARTICLE;

ANTIBODIES, MONOCLONAL; BIOTECHNOLOGY; CHROMATOGRAPHY, ION EXCHANGE; ISOELECTRIC POINT; VIRUSES;

PORCINE PARVOVIRUS;

EID: 84862703534     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.24480     Document Type: Article

References (32)

1. Adcock WL, MacGregor A, Davies JR, Hattarki M, Anderson DA, Goss NH. 1998. Chromatographic removal and heat inactivation of hepatitis A virus during manufacture of human albumin. Biotechnol Appl Biochem 28: 85- 94.
2. Arunakumari A, Wang J, Ferreira G. 2007. Improved downstream process design for human monoclonal antibody production. Biopharm Int 20: 36- 40.
3. Bolton G, Cabatingan M, Rubino M, Lute S, Brorson K, Bailey M. 2005. Normal-flow virus filtration: Detection and assessment of the endpoint in bio-processing. Biotechnol Appl Biochem 42: 133- 142.
4. Brorson K, Shen H, Lute S, Perez JS, Frey DD. 2008. Characterization and purification of bacteriophages using chromatofocusing. J Chromatogr A 1207: 110- 121.
5. Coetzee JN, Lecatsas G, Coetzee WF, Hedges RW. 1979. Properties of R plasmid R772 and the corresponding pilus-specific phage PR772. J Gen Microbiol 110: 263- 273.
6. Connell-Crowley L, Nguyen T, Bach J, Chinniah S, Bashiri H, Gillespie R, Moscariello J, Hinckley P, Dehghani H, Vunnum S, Vedantham G. 2012. Cation exchange chromatography provides effective retrovirus clearance for antibody purification processes. Biotechnol Bioeng 109: 157- 165.
7. Dowd SE, Pillai SD, Wang S, Corapcioglu MY. 1998. Delineating the specific influence of virus isoelectric point and size on virus adsorption and transport through sandy soils. Appl Environ Microbiol 64: 405- 410.
8. Duhamel RC, Schur PH, Brendel K, Meezan E. 1979. pH gradient elution of human IgG1, IgG2 and IgG4 from protein A-sepharose. J Immunol Methods 31: 211- 217.
9. Follman DK, Fahrner RL. 2004. Factorial screening of antibody purification processes using three chromatography steps without protein A. J Chromatogr A 1024: 79- 85.
10. Forsgren A, Sjoquist J. 1966. " Protein A" from S. aureus. I. Pseudo-immune reaction with human gamma-globulin. J Immunol 97: 822- 827.
11. Ghose S, Allen M, Hubbard B, Brooks C, Cramer SM. 2005. Antibody variable region interactions with Protein A: Implications for the development of generic purification processes. Biotechnol Bioeng 92: 665- 673.
12. Ghose S, McNerney T, Hubbard B. 2007a. Protein A affinity chromatography for capture and purification of monoclonal antibodies and fc-fusion proteins: Practical considerations for process development. In: Shukla A, Etzel M, Gadam S, editors. Process scale bioseparations for the biopharmaceutical industry. New York: Taylor and Francis. p 463- 490.
13. Ghose S, Hubbard B, Cramer SM. 2007b. Binding capacity differences for antibodies and Fc-fusion proteins on protein A chromatographic materials. Biotechnol Bioeng 96: 768- 779.
14. Goding JW. 1978. Use of staphylococcal protein A as an immunological reagent. J Immunol Methods 20: 241- 253.
15. Hahn R, Schlegel R, Jungbauer A. 2003. Comparison of protein A affinity sorbents. J Chromatogr B Analyt Technol Biomed Life Sci 790: 35- 51.
16. Hjelm H, Sjodahl J, Sjoquist J. 1975. Immunologically active and structurally similar fragments of protein A from Staphylococcus aureus. Eur J Biochem 57: 395- 403.
17. Kärber G. 1931. Article on the collective handling of pharmacological array effort. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 162: 480- 483.
18. Lain B, Cacciuttolo M, Zarbis-Papastoitsis G. 2009. Development of a high-capacity MAb capture step based on cation-exchange chromatography. Bioprocess Int 7: 26- 34.
19. Lute S, Aranha H, Tremblay D, Liang D, Ackermann HW, Chu B, Moineau S, Brorson K. 2004. Characterization of coliphage PR772 and evaluation of its use for virus filter performance testing. Appl Environ Microbiol 70: 4864- 4871.
20. Lute S, Bailey M, Combs J, Sukumar M, Brorson K. 2007. Phage passage after extended processing in small-virus-retentive filters. Biotechnol Appl Biochem 47: 141- 151.
21. Lute S, Wang H, Sanchez D, Barletta J, Chen Q, Brorson K. 2009. Multiplex RT Q-PCR assay for simultaneous quantification of three viruses used for validation of virus clearance by biopharmaceutical production. Biologicals 37: 331- 337.
22. Michen B, Graule T. 2010. Isoelectric points of viruses. J Appl Microbiol 109: 388- 397.
23. Miesegaes G, Bailey M, Willkommen H, Chen Q, Roush D, Blümel J, Brorson K. 2010a. Proceedings of the 2009 Viral Clearance Symposium. Dev Biol (Basel) 133: 3- 101.
24. Miesegaes G, Lute S, Brorson K. 2010b. Analysis of viral clearance unit operations from monoclonal antibody regulatory submissions. Biotechnol Bioeng 106: 238- 246.
25. Necina R, Amatschek K, Jungbauer A. 1998. Capture of human monoclonal antibodies from cell culture supernatant by ion exchange media exhibiting high charge density. Biotechnol Bioeng 60: 689- 698.
26. O'Leary RM, Feuerhelm D, Peers D, Xu Y, Blank GS. 2001. Determining the useful lifetime chromatography resins-Prospective small-scale studies. BioPharm Appl Technol Biopharm 14: 10- 18.
27. PDA. 2008. Technical report 41: Virus retentive filtration. Bethesda, MD, Parenteral Drug Association. Ref Type: Report.
28. Seely RJ, Wight HD, Rudge SR, Slaff GF. 1994. Validation of chromatography resin useful life. Abstracts of Papers of the American Chemical Society 207: 90-BTEC.
29. Strauss DM, Lute S, Tebaykina Z, Frey DD, Ho C, Blank GS, Brorson K, Chen Q, Yang B. 2009. Understanding the mechanism of virus removal by Q sepharose fast flow chromatography during the purification of CHO-cell derived biotherapeutics. Biotechnol Bioeng 104: 371- 380.
30. Vasilyeva E, Fajardo H, Bove P, Brown F, Kretschmer M. Development of a chip-based electrophoresis method for the determination of half-antibody molecules in IgG4. Presented at WCBP 2002. 1-27-2002. Ref Type: Abstract.
31. Williams PP, Pirtle EC, Coria MF. 1982. Isoelectric focusing of infectious particles of porcine pseudorabies virus strains in granulated dextran gels. Can J Comp Med 46: 65- 69.
32. Zhang M, Lute S, Norling L, Hong C, Safta A, O'Connor D, Bernstein LJ, Wang H, Blank G, Brorson K, Chen Q. 2008. A novel, Q-PCR based approach to measuring endogenous retroviral clearance by capture Protein A chromatography. Biotechnol Bioeng 102: 1438- 1447.